Home Featured Page 115

Featured

Latest

What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and Scaling Psychedelic Care

Film Club: Music for Mushrooms

Psychedelic Approvals on Track, Advocacy in Flux: A Washington Dispatch on FDA, Election Year and ‘Ibogaine Exceptionalism’

Betty Aldworth & Ismail Ali: MAPS Co-Executive Directors on Leadership, Research, and the Future of Psychedelics

COMPASS Pathways to participate in upcoming Cowen 43rd Annual Health Care...

GH Research Reports Full Year 2022 Financial Results and Provides Business...

Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player...

atai Life Sciences to Participate in the Cowen 43rd Annual Health...

Mycoprenuer Podcast – Joe Moore & Kyle Buller: Psychedelics Today

Psychedelic Health – Psychedelics Today: improving access to psychedelic therapy training

Small Pharma to Present at Cowen’s 43rd Annual Health Care Conference

Optimi Health Enters Australian Medical MDMA And Psilocybin Market With Mind...

Algernon Pharmaceuticals Announces 4 for 1 Forward Share Split

EDITOR PICKS

What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and...

Film Club: Music for Mushrooms

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and Scaling Psychedelic Care

test

Film Club: Music for Mushrooms

Psychedelic Approvals on Track, Advocacy in Flux: A Washington Dispatch on FDA, Election Year and ‘Ibogaine Exceptionalism’

Betty Aldworth & Ismail Ali: MAPS Co-Executive Directors on Leadership, Research, and the Future of Psychedelics

COMPASS Pathways to participate in upcoming Cowen 43rd Annual Health Care...

GH Research Reports Full Year 2022 Financial Results and Provides Business...

Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player...

atai Life Sciences to Participate in the Cowen 43rd Annual Health...

Mycoprenuer Podcast – Joe Moore & Kyle Buller: Psychedelics Today

Psychedelic Health – Psychedelics Today: improving access to psychedelic therapy training

Small Pharma to Present at Cowen’s 43rd Annual Health Care Conference

Convergence: Canceled

Optimi Health Enters Australian Medical MDMA And Psilocybin Market With Mind...

Algernon Pharmaceuticals Announces 4 for 1 Forward Share Split

EDITOR PICKS

What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and...

test

Film Club: Music for Mushrooms

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY